Remedium Capital Partners, LLC
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 12, 2026), Remedium Capital Partners, LLC reported 6 stock positions worth $170.2 million. Its top holding was Spyre Therapeutics (SYRE) at 28.0% of the portfolio, followed by Oruka Therapeutics (ORKA, 27.6%) and Apogee Therapeutics (APGE, 25.9%).
- Most Recent 13F
- Q2 2026
- Location
- WEST PALM BEACH, FL
- CIK
- 0002104501
- Portfolio Value
- $170.2M (Q4 2025)
- SEC Filing
- 0002104501-26-000004 ↗ filed Feb 12, 2026
Holdings Value
Holdings 6 stocks · $170.2M
| SYRE Spyre Therapeutics Inc. | 28.03% | 1,456,231 | $47.7M | — |
| ORKA Oruka Therapeutics Inc. | 27.64% | 1,552,414 | $47.1M | — |
| APGE Apogee Therapeutics Inc. | 25.88% | 583,591 | $44.0M | — |
| JBIO Jade Biosciences Inc. | 14.30% | 1,577,750 | $24.3M | — |
| CBIO Crescent Biopharma Inc. | 2.52% | 361,250 | $4.3M | — |
| DMRA Damora Therapeutics Inc. filed as GALECTO INC | 1.63% | 120,473 | $2.8M | — |
Portfolio Sells Q4 2025
No earlier filing to compare with.
Portfolio Buys Q4 2025
No earlier filing to compare with.